ArticleExperimental & molecular medicine2026
TRANsCre-DIONE transdifferentiates scar-forming reactive astrocytes into functional motor neurons.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- The bHLH Transcription Factors in Neural Development and Therapeutic Applications for Neurodegenerative Diseases.International journal of molecular sciences · 2022Review
- Challenges and Opportunities of Targeting Astrocytes to Halt Neurodegenerative Disorders.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
In spinal cord injury (SCI), the scar-forming reactive astrocytes with upregulated glial fibrillary acidic protein (GFAP) proliferate aberrantly near the injury site, representing a potential cellular source for transdifferentiation into neurons to replenish dead neurons. However, the conventional use of GFAP promoter to target reactive astrocytes has two inherent problems: inadvertent conversion of normal astrocytes and low efficiency due to progressive weakening of promoter activity during transdifferentiation. Here, we present TRANsCre-DIONE, a dual-promoter split-Cre system combining GFAP and Lcn2 regulatory elements with Cre-dependent Neurog2 expression under the EF1α promoter, enabling selective targeting of scar-forming reactive astrocytes. This approach achieved 87% conversion efficiency and 96% specificity in vivo. After SCI, TRANsCre-DIONE caused transdifferentiation into Isl1-positive and ChAT-positive motor neurons, reduced astrogliosis, enhanced regeneration in surrounding cells, and a significant motor recovery. These findings suggest that TRANsCre-DIONE enables efficient and selective astrocyte-to-neuron conversion and represents a promising strategy for SCI repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.